Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News LakeShore Biopharma Co Ltd LSB

Consumer Cyclical Healthcare Advertising Agencies Biotechnology

Recent & Breaking News (NDAQ:LSB)

LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation

PR Newswire 9 days ago

Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024

PR Newswire September 10, 2024

LakeShore Biopharma Announces Leadership Transitions

PR Newswire September 4, 2024

LakeShore Biopharma Announces Financial Results for Fiscal Year 2024

PR Newswire August 15, 2024

LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition

PR Newswire July 5, 2024

YS Biopharma Announces Name Change to LakeShore Biopharma

PR Newswire May 24, 2024

YS Biopharma Announces Results of Extraordinary General Meeting

PR Newswire May 21, 2024

YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer

PR Newswire May 7, 2024

YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

PR Newswire April 29, 2024

YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

PR Newswire April 19, 2024

YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine

PR Newswire April 18, 2024

YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024

PR Newswire April 16, 2024

YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine

PR Newswire April 9, 2024

YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility

PR Newswire April 3, 2024

YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries

PR Newswire March 5, 2024

YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024

PR Newswire February 22, 2024

/C O R R E C T I O N -- YS Biopharma Co., Ltd./

PR Newswire February 18, 2024

YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting

PR Newswire February 16, 2024

YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governance

PR Newswire February 14, 2024

YS Biopharma Announces Appointment of New Directors

PR Newswire February 14, 2024
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested